TGFBR2 and neoplasm: The TGF‐B1/TGFBR2 signalling axis mediated tumour‐CD4+ T cell communication, suppressing CD4+ T cell anti‐tumour activity and resulting in reduced CD4+ T cell enrichment and poor prognosis.